Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.D., has been appointed Oncology Development Head, effective July 25, 2016. Dr. Namouni will be responsible for leading the execution of a comprehensive development strategy for the company’s robust oncology pipeline from the early development stage through commercialization. He will continue to report to Francis Cuss, MB Bchir, FRCP, executive vice president, chief scientific officer, and remain a member of the R&D Leadership Team.